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Background:  Anthracyclines (AC) are effective antineoplastic drugs whose use is limited by cardiotoxicity. Although the mechanisms of 
anthracycline-mediated cardiotoxicity (ACT) are not fully understood, free radicals play an important role. The NADPH oxidases (NOX) have been 
demonstrated in the myocardium and are major sources of free radicals after AC treatment. The effect of NOX inhibition on ACT has not been well 
studied.
Methods:  Three month old mice (males =females) were divided into a control group (n=20) and treatment group (n=12). All mice were given 
weekly AC IV injection for three weeks for a total dose of 20 mg/kg. The treatment group was also given the NOX inhibitor apocynin in their drinking 
water at a concentration of 2 g/l from one day prior to the 1st AC injection until 1 week after the 3rd AC injection. Cardiac dimension and function 
were evaluated by echocardiography at baseline and at 1 week after the 2nd and the 3rd dose of AC injection. Cardiac catheterization was 
performed to evaluate hemodynamics 1 week after the final AC dose prior to sacrifice.
Results:  Mortality in the treatment group (20%) was lower than that in the control group (60%) 1 week after the final dose AC injection (P<0.05). 
Compared with the control group, the treatment group had higher LV systolic pressure (79.1±6.2 vs. 62.2±9.5 mmHg, P<0.05), improved dP/dT max 
(6783±1580 vs. 3726±922 mmHg/s, P<0.001), dP/dT min (-6089±1458 vs. -3594±823 mmHg/s, P<0.001) and lower LVEDP (4.8 ±2.8 vs. 9.9 
±3.4 mmHg P<0.05). The treatment group also showed significantly less decrease in shortening fraction (-5.3±% 7.8 vs. - 13.1± 8 %, P<0.05) by 
echocardiography.
Conclusions:  The addition of a NOX inhibitor to AC therapy reduces mortality and improves LV systolic and diastolic function in a mouse model 
of ACT. Once the mechanism of this effect is defined, NOX inhibition may represent a therapeutic modality to reduce the impact of this important 
clinical problem.
